W. Thomas Hodgson appointed to board of Helix BioPharma Corp.

About this update from Helix Biopharma Corp.

[{"type":"text","content":"\n\n\n\nAURORA, ON, April 7 /CNW/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt:\nWKN 918864)\n\n\nHelix BioPharma Corp. today announced that the board of directors has\nincreased the authorized number of directors from six to seven and has\nappointed Mr. W. Thomas Hodgson as director to fill the newly created\nposition. Mr. Hodgson will also serve as chair of the three member Audit\nCommittee, replacing Mr. Jack Kay who previously held the position.\n\n\nMr. Hodgson is currently senior partner and chairman of Greenbrook\nCapital Partners and acts as an advisor to the chairman of Magna Entertainment\nCorp. Mr. Hodgson's prior roles include senior positions with Canadian\nfinancial institutions and U.K. based companies.\n\n\nDonald Segal, chief executive officer of Helix BioPharma, said, "Tom's\ndiverse professional background and capital markets experience will be an\ninvaluable resource to the board. In addition, his extensive knowledge of\ncomplex financial matters makes him ideally suited to chair our audit\ncommittee. We look forward to his contributions."\n\n\nAbout Helix BioPharma Corp.\n\n\nHelix BioPharma Corp. is a biopharmaceutical company specializing in the\nfield of cancer therapy. The company is actively developing innovative\nproducts for the prevention and treatment of cancer based on its proprietary\ntechnologies. Helix's product development initiatives include its Topical\nInterferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed\non the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich\nand Stuttgart Stock Exchanges under the same symbol.\n\n\nThe Toronto Stock Exchange has not reviewed and does not accept\n\n\nresponsibility for the adequacy or accuracy of the content of this News\n\n\nRelease.\n\n\n","length":1867,"tagName":"div"}]

More updates from Helix Biopharma Corp.